Recent Posts
- AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference
- AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
- AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
- AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
Recent Comments
No comments to show.